Ambalal Sarabhai Enterprises Ltd. (AMBALALSA): Ambalal Sarabhai Enterprises Share Price Rises 8.15% Today

Ambalal Sarabhai Enterprises Ltd. traded at Rs 45.93, up 8.15% today, with a market capitalisation of Rs 325.46 crore.

Ambalal Sarabhai Enterprises Share Price moved higher to Rs 45.93 on 17 August 2026, rising 8.15% from the previous close of Rs 42.47 and taking the company’s market capitalisation to Rs 325.46 crore. That puts Ambalal Sarabhai Enterprises Ltd. among the stocks in news today, especially because the move was large enough to qualify under the price-rise screen for its Micro Cap category.

For investors tracking Ambalal Sarabhai Enterprises Share Price Today, the verified data confirms a sharp single-session gain backed by active trading across exchanges. The stock opened at Rs 41.16, touched an intraday high of Rs 46.70, and stayed well above the prior close through the session window captured in this update. Total traded volume stood at 3,27,713 shares, including 2,77,681 shares on NSE and 50,032 shares on BSE, while reported BSE turnover was Rs 0.23 crore.

Why is the stock trending? The supplied data clearly establishes the share price rise and strong intraday range, although it does not establish a company-specific catalyst. What matters next is whether today’s price action is matched by sustainable market interest, how the valuation compares with the Pharmaceuticals & Drugs benchmark, and whether profitability metrics such as ROE and ROCE justify the attention. In this Univest analysis, the focus is on price action, fundamentals, sector context, peer positioning and what investors should monitor next.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 45.93
Previous Close	Rs 42.47
Today’s Change	+Rs 3.46 (+8.15%)
Day Open	Rs 41.16
Day High	Rs 46.7
Day Low	Rs 41.16
Current Volume (BSE)	50,032
BSE Traded Volume	50,032
NSE Traded Volume	2,77,681
Combined NSE + BSE Volume	3,27,713
Turnover	Rs 0.23 crore
Market Capitalisation	Rs 325.46 crore
Market Cap Category	Micro Cap

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) traded at Rs 45.93. versus the previous close of Rs 42.47, a rise of 8.15%. The stock opened at Rs 41.16, reached Rs 46.7, touched Rs 41.16. Reported volume was 50,032.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 325.46 crore
P/E Ratio	18.28x
P/B Ratio	2.06x
ROE	48.74%
ROCE	45.53%
EPS	Rs 2.32
Dividend Yield	0%

Ambalal Sarabhai Enterprises Ltd. was valued at a P/E ratio of 18.28x, a P/B ratio of 2.06x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 48.74% and ROCE of 45.53%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 2.32, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Ambalal Sarabhai Enterprises Share Price is attracting attention not only because of today’s rise but also because the company’s reported profitability metrics stand out against many smaller listed peers. With a market capitalisation of Rs 325.46 crore, the company sits firmly in the micro cap bracket, which indicates size but not, by itself, business quality or valuation comfort.

On valuation, the stock is trading at a P/E ratio of 18.28 and a P/B ratio of 2.06. Those figures matter because they can be read against the company’s earnings and balance-sheet efficiency. EPS is Rs 2.32, which means the current stock price is being valued at 18.28 times earnings per share based on the supplied figure. The P/B of 2.06 means the market values the company at a little over two times its accounting net worth per share. Dividend yield stands at 0, so the current investment case reflected in the supplied data is not based on an ongoing cash yield.

The more striking numbers are return ratios. ROE is 48.74% and ROCE is 45.53%, both unusually strong in absolute terms. ROE measures return generated on shareholder equity, while ROCE measures return on capital employed across the operating base. When both are this high, they naturally increase investor interest because they suggest strong capital efficiency in the reported figures. That said, valuation and returns must be read together. A modest-to-mid P/E can look more compelling when paired with high ROE and ROCE, and that is part of why Ambalal Sarabhai Enterprises Stock News is drawing added scrutiny today.

There is also an important balance within the numbers. The stock is not priced at the kind of very high P/E seen in several listed pharmaceuticals peers, yet it is also not trading at a deep discount to book value. So the picture from a fundamental analysis perspective is one of meaningful profitability with a market valuation that requires comparison against the broader Healthcare and Pharmaceuticals & Drugs set. That benchmark view helps determine whether the current price rise is occurring in an already expensive stock or in one that still screens differently from sector averages.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	18.28x
Benchmark Median P/E	26.47x
Benchmark Average P/E	40.28x
Benchmark P/E Range	2.98x to 361.02x
Company P/B Ratio	2.06x
Benchmark Median P/B	1.77x
Company ROE	48.74%
Benchmark Median ROE	9.91%
Company ROCE	45.53%
Benchmark Median ROCE	12.79%
Company Market Capitalisation	Rs 325.46 crore
Benchmark Median Market Cap	Rs 137.8 crore

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a P/E ratio of 18.28x, which is below the benchmark median of 26.47x, a difference of -30.94%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a ROE of 48.74%, which is above the benchmark median of 9.91%, a difference of +391.83%. Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a ROCE of 45.53%, which is above the benchmark median of 12.79%, a difference of +255.98%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Ambalal Sarabhai Enterprises Share Price sits within the Healthcare sector and the Pharmaceuticals & Drugs industry, so the most useful comparison is with the same-industry benchmark rather than with the broader Indian stock market. The supplied benchmark covers 139 companies, giving a meaningful sector snapshot for valuation and profitability context.

On valuation, the company’s P/E ratio of 18.28 is below the same-industry median P/E of 26.47 and well below the average P/E of 40.28. The industry P/E range is wide, from 2.98 to 361.02 across 105 companies with available P/E data, which shows how dispersed valuations are inside this segment. Relative to that range, Ambalal Sarabhai Enterprises Ltd. is positioned below both the median and average, which suggests the stock is not priced at the richer end of the Pharmaceuticals & Drugs universe on earnings multiples alone.

The P/B comparison is more balanced. The company’s P/B is 2.06 against an industry median of 1.77 and an average of 2.33 across 138 companies. That places the stock above the median but below the average on book-value valuation. In other words, the share price is not unusually cheap on book value, but it is also not at the top end of the peer distribution.

Profitability metrics stand out more strongly. Company ROE of 48.74% is far above the industry median of 9.91% and average of 7.30. Company ROCE of 45.53% is also far above the median of 12.79% and average of 14.83. Market-cap context adds another layer: Ambalal Sarabhai Enterprises Ltd. has a market capitalisation of Rs 325.46 crore, above the benchmark median of Rs 137.80 crore but below the average of Rs 481.52 crore, within an industry range of Rs 2.19 crore to Rs 2,985.15 crore. For Univest readers, this creates an interesting setup: a micro cap healthcare name with lower-than-benchmark P/E but much higher-than-benchmark return ratios.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,985.15	184.72	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,827.67	68.16	6.74	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.26	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	46.15	1.77	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	58.41	8.73	11.42	13.15

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a P/E ratio of 18.28x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 48.74% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 45.53% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a market capitalisation of Rs 325.46 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Ambalal Sarabhai Enterprises Share Price becomes more interesting when viewed against a selected peer set from the same Healthcare, Pharmaceuticals & Drugs space. The company’s market capitalisation of Rs 325.46 crore is much smaller than peers such as Dishman Carbogen Amcis Ltd. at Rs 2,985.15 crore, Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore and Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore. That size gap is important because smaller market-cap stocks often move more sharply in single sessions.

On valuation, Ambalal Sarabhai Enterprises Ltd. trades at a P/E of 18.28, lower than Dishman Carbogen Amcis at 184.72, Beta Drugs at 68.16, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Sai Parenteral’s at 171.00, Venus Remedies at 20.56 and NGL Fine-Chem at 37.40. Among peers with supplied P/E data, only Venus Remedies is relatively close at 20.56, while several others trade at substantially higher earnings multiples. That comparison supports the view that the company is not expensive on P/E versus this peer basket.

On P/B, the company’s 2.06 sits above Dishman Carbogen Amcis at 0.45, above Ind-Swift Laboratories at 1.77 and above Solara Active Pharma Sciences at 1.93, but below Hikal at 2.26, Sai Parenteral’s at 3.13, Venus Remedies at 3.48, Beta Drugs at 6.74, NGL Fine-Chem at 6.15 and Fredun Pharmaceuticals at 8.73. That places the stock in the middle of the peer range on book-value valuation.

The strongest relative point is profitability. ROE at 48.74% is higher than Beta Drugs at 18.65%, Hikal at 15.22%, Fredun Pharmaceuticals at 11.42%, Venus Remedies at 9.85% and NGL Fine-Chem at 27.90, while ROCE at 45.53% is ahead of Beta Drugs at 22.17%, Hikal at 16.15%, Fredun Pharmaceuticals at 13.15%, Sai Parenteral’s at 12.97% and NGL Fine-Chem at 33.91. So even though the company is far smaller by market cap, its reported return ratios are stronger than many larger peers. That contrast helps explain why today’s Ambalal Sarabhai Enterprises Share Price rise is drawing close stock analysis attention on Univest.

Why Investors Are Watching Ambalal Sarabhai Enterprises

Ambalal Sarabhai Enterprises Share Price is on investor radar because today’s move combined a meaningful single-day gain, a strong intraday range and standout profitability metrics relative to the Pharmaceuticals & Drugs benchmark. The supplied data does not identify a company-specific trigger, but it does show why the stock has entered the conversation around top gainers today and stocks rising today.

• Verified price action: The stock rose 8.15% to Rs 45.93 from Rs 42.47, with an intraday high of Rs 46.70.
• Category relevance: As a Micro Cap stock, the move cleared the qualifying bar for its category’s price-rise screen.
• Trading activity: Total volume reached 3,27,713 shares across NSE and BSE, with BSE turnover of Rs 0.23 crore.
• Valuation context: P/E of 18.28 is below the same-industry median of 26.47 and average of 40.28.
• Profitability context: ROE of 48.74% and ROCE of 45.53% are well above industry medians and averages.

The next things to monitor are whether the stock continues holding closer to the upper end of today’s range, whether volumes remain active after this share price rise, and how investors interpret the gap between the company’s strong returns profile and its relatively moderate earnings multiple. That mix is why Univest sees this as a stock worth tracking, even without assigning any recommendation.

About Ambalal Sarabhai Enterprises

Ambalal Sarabhai Enterprises Ltd. is being viewed here through the lens of its listed-market data and sector classification. The company is classified under the Healthcare sector and the Pharmaceuticals & Drugs industry, placing it within a segment of the market that includes a wide mix of drug manufacturers, pharma product companies and related healthcare businesses.

That industry classification matters because it shapes how the market compares valuation and profitability. In pharmaceuticals, investors often study P/E, P/B, ROE and ROCE closely because these measures can reveal whether a company is generating strong returns on capital while trading at a premium or discount to peers. For Ambalal Sarabhai Enterprises Ltd., the current listed-market context is especially noteworthy: a market capitalisation of Rs 325.46 crore, a P/E of 18.28, a P/B of 2.06, and very strong reported ROE and ROCE figures of 48.74% and 45.53% respectively.

The wider Pharmaceuticals & Drugs benchmark in the supplied data spans 139 companies, ranging from very small businesses to companies with market capitalisation approaching Rs 2,985.15 crore. That places Ambalal Sarabhai Enterprises Ltd. in the smaller-cap portion of a diverse listed industry. For readers following Ambalal Sarabhai Enterprises Share News and Healthcare market news, the company is best understood as a micro cap pharmaceuticals-linked stock whose current investor visibility comes from a combination of today’s price rise and above-benchmark profitability ratios.

Track Ambalal Sarabhai Enterprises Share Price on Univest

Use Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Ambalal Sarabhai Enterprises Share Price more closely can use Univest to track live share price movements, 52-week levels, market capitalisation, valuation ratios, profitability measures and broader stock analysis indicators in one place. Univest also helps users monitor changes in price action across NSE and BSE, compare the stock with listed peers, and place the company inside its Healthcare and Pharmaceuticals & Drugs sector context.

For daily market watchers, that makes it easier to revisit Ambalal Sarabhai Enterprises Share Price Today after a top-gainer move, compare it with other market movers, and assess whether the combination of earnings multiple, return ratios and sector positioning continues to stand out. Univest coverage is designed to help readers track verified data points rather than react to noise.

Frequently Asked Questions

What is Ambalal Sarabhai Enterprises Share Price today?

Ans. Ambalal Sarabhai Enterprises Share Price today was Rs 45.93 at the time of this update. The stock was up 8.15% from the previous close of Rs 42.47, making it one of the notable gainers in today’s session.

Why is Ambalal Sarabhai Enterprises rising today?

Ans. The supplied data confirms that the stock rose 8.15% in a single session and cleared the price-rise screen for its Micro Cap category. It confirms the market move and active trading, but the data set does not identify a specific.

What were the day’s open, high and low for Ambalal Sarabhai Enterprises?

Ans. The stock opened at Rs 41.16, touched an intraday high of Rs 46.70 and recorded a day low of Rs 41.16. That range shows the price moved sharply higher from the opening level during the trading session.

How much volume was traded in Ambalal Sarabhai Enterprises today?

Ans. Total traded volume stood at 3,27,713 shares, including 2,77,681 shares on NSE and 50,032 shares on BSE. Reported BSE turnover was Rs 0.23 crore, confirming that the price rise was accompanied by active market participation.

What is the market capitalisation of Ambalal Sarabhai Enterprises?

Ans. Ambalal Sarabhai Enterprises Ltd. had a market capitalisation of Rs 325.46 crore in this update. That places it in the Micro Cap category, which is relevant because today’s 8.15% gain was assessed within that size bucket.

Is Ambalal Sarabhai Enterprises expensive on P/E compared with its industry?

Ans. The company’s P/E ratio is 18.28, below the same-industry median of 26.47 and average of 40.28. Based on the supplied Pharmaceuticals & Drugs benchmark, the stock is not trading at the richer end of the industry P/E range.

How does Ambalal Sarabhai Enterprises compare on P/B ratio?

Ans. The stock’s P/B ratio is 2.06. That is above the industry median P/B of 1.77 but below the average of 2.33, placing Ambalal Sarabhai Enterprises in the middle zone of the benchmark on book-value valuation.

What do the ROE and ROCE figures show for Ambalal Sarabhai Enterprises?

Ans. Ambalal Sarabhai Enterprises reported ROE of 48.74% and ROCE of 45.53%. Both figures are far above the industry medians of 9.91% and 12.79, indicating much stronger reported capital efficiency than the broader benchmark set.

What are the EPS and dividend yield of Ambalal Sarabhai Enterprises?

Ans. The supplied EPS is Rs 2.32, which represents earnings attributable to each share, while dividend yield is 0. This means the current listed data highlights earnings and valuation more than historical cash payout support.

How does Ambalal Sarabhai Enterprises compare with listed pharma peers?

Ans. Its market cap of Rs 325.46 crore is smaller than peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal, but its P/E of 18.28 is lower than many peers and its ROE and ROCE are stronger than several larger.